Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Name
P-MUC1C-ALLO1-001
Description
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Trial arms
Trial start
2022-02-15
Estimated PCD
2026-04-01
Trial end
2039-04-01
Status
Recruiting
Phase
Early phase I
Treatment
P-MUC1C-ALLO1 CAR-T cells
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
Arms:
P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
Rimiducid
Rimiducid (safety switch activator) may be administered as indicated.
Arms:
P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
Size
100
Primary endpoint
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Baseline through Day 28
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Baseline through 15 years
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Baseline through 15 years
Eligibility criteria
Inclusion Criteria:
* Males or females, Subjects ≥18 years with life expectancy \>3 months
* Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer, refractory to standard of care therapy or ineligible or refused other existing treatment options
* Must have progressed during or after last therapy and have measurable disease
* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
* Must have adequate vital organ function within pre-determined parameters
* Must have archived tumor tissue available or consent to a biopsy collection
* Must be willing to practice birth control
* Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
* Must have recovered from toxicities due to prior therapies
Exclusion Criteria:
* Has inadequate venous access
* Has an active second malignancy in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
* Is pregnant or lactating
* Has a history of or active autoimmune disease
* Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
* Has an active systemic (viral, bacterial, or fungal) infection
* Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
* Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
* Has received anticancer medications within 2 weeks of the time of initiating conditioning chemotherapy
* Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
* Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
* Has known CNS metastases or symptomatic CNS involvement
* Has a history of significant liver disease or active liver disease
* Has a history of known genetic predisposition to HLH/MAS
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at recommended phase 2 dose (RP2D)', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-04-23
1 organization
2 products
9 indications
Organization
Poseida TherapeuticsProduct
P-MUC1C-ALLO1 CAR-T cellsIndication
Breast CancerIndication
Ovarian CancerIndication
Lung CancerIndication
Colorectal CancerIndication
Pancreatic CancerIndication
Renal Cell CarcinomaIndication
Nasopharyngeal CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Stomach CancerProduct
Rimiducid